138 related articles for article (PubMed ID: 37276851)
1. Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
Hayashi T; Shimokawa M; Matsuo K; Uchiyama M; Kawada K; Nakano T; Egawa T
Oncology; 2023; 101(9):584-590. PubMed ID: 37276851
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Mizuki F; Matsuo K; Kawada K; Nakano T; Egawa T
Support Care Cancer; 2021 Sep; 29(9):5029-5035. PubMed ID: 33590260
[TBL] [Abstract][Full Text] [Related]
3. 5HT
Hayashi T; Shimokawa M; Matsuo K; Nishimura J; Iihara H; Nakano T; Egawa T
Cancer Sci; 2021 Feb; 112(2):744-750. PubMed ID: 33274555
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.
Hayashi T; Shimokawa M; Matsuo K; Kawada K; Nakano T; Egawa T
Expert Opin Pharmacother; 2023; 24(18):2221-2226. PubMed ID: 38009903
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 5HT3RA, DEX, and NK1RA for the prevention of FOLFIRINOX-induced nausea and vomiting in patients with pancreatic cancer: a retrospective cohort study.
Hishida-Sadaka S; Iihara H; Ohata K; Matsuoka S; Watanabe D; Iwashita T; Uemura S; Shimizu M; Suzuki A
Support Care Cancer; 2023 Oct; 31(12):657. PubMed ID: 37884842
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.
Miya T; Kobayashi K; Hino M; Ando M; Takeuchi S; Seike M; Kubota K; Gemma A;
Springerplus; 2016; 5(1):2080. PubMed ID: 28018788
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
9. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
11. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Tsuji D; Nakagaki S; Yonezawa I; Suzuki K; Yokokawa T; Kawasaki Y; Yamaguchi T; Kawaguchi T; Hatori M; Matsumoto T; Sakata Y; Yamamoto K; Nishimura T; Kogure Y; Hayashi T; Osawa M; Itoh K; Watanabe M
Invest New Drugs; 2024 Feb; 42(1):44-52. PubMed ID: 38055127
[TBL] [Abstract][Full Text] [Related]
12. Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.
Watanabe Y; Saito Y; Mitamura T; Takekuma Y; Sugawara M
J Pharm Health Care Sci; 2021 Jun; 7(1):21. PubMed ID: 34059157
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
[TBL] [Abstract][Full Text] [Related]
14. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
Sci Rep; 2023 Jan; 13(1):1257. PubMed ID: 36690734
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
17. Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies.
Yeo W; Li L; Lau TK; Lai KT; Chan VT; Wong KH; Yip CC; Pang E; Cheung M; Chan V; Kwok CC; Suen JJ; Mo FK
Cancer Biol Med; 2021 Mar; 18(3):825-32. PubMed ID: 33710814
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
Rugo HS; Rossi G; Rizzi G; Aapro M
Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
